Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab N01 + sintilimab + TKI in second-line HCC after PD-1/PD-L1 + bevacizumab
ChiCTR2600129393Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and sintilimab in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Objective response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ipilimumabsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600129393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129393.